Overview

Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2018-02-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2 diabetes mellitus who are being treated with once-daily dosing of DPP-4 inhibitor.

Phase:

Phase 4

Details

Lead Sponsor:

Takeda

Treatments:

Alogliptin
Dipeptidyl-Peptidase IV Inhibitors